Refine
Year of publication
- 2024 (8)
- 2023 (18)
- 2022 (20)
- 2021 (12)
- 2020 (13)
- 2019 (16)
- 2018 (22)
- 2017 (12)
- 2016 (44)
- 2015 (30)
- 2014 (47)
- 2013 (29)
- 2012 (40)
- 2011 (28)
- 2010 (35)
- 2009 (30)
- 2008 (16)
- 2007 (20)
- 2006 (17)
- 2005 (20)
- 2004 (15)
- 2003 (14)
- 2002 (19)
- 2001 (18)
- 2000 (12)
- 1999 (16)
- 1998 (31)
- 1997 (25)
- 1996 (19)
- 1995 (36)
- 1994 (29)
- 1993 (21)
- 1992 (27)
- 1991 (15)
- 1990 (20)
- 1989 (20)
- 1988 (19)
- 1987 (16)
- 1986 (11)
- 1985 (7)
- 1984 (10)
- 1983 (10)
- 1982 (3)
- 1981 (3)
- 1980 (3)
- 1979 (8)
- 1978 (2)
- 1976 (2)
- 1975 (3)
- 1973 (2)
- 1972 (2)
- 1971 (2)
Institute
- Fachbereich Chemie und Biotechnologie (917) (remove)
Language
- English (552)
- German (362)
- Multiple languages (2)
- Spanish (1)
Document Type
- Article (603)
- Patent (119)
- Book (66)
- Conference: Meeting Abstract (55)
- Conference Proceeding (35)
- Part of a Book (21)
- Report (6)
- Doctoral Thesis (4)
- Bachelor Thesis (3)
- Conference Poster (1)
Keywords
- Heparin (3)
- Bacillaceae (2)
- Biorefinery (2)
- Biotechnological application (2)
- Butanol (2)
- Chemometrics (2)
- IR spectroscopy (2)
- NMR spectroscopy (2)
- Principal component analysis (2)
- Standardization (2)
A microfluidic chip integrating amperometric enzyme sensors for the detection of glucose, glutamate and glutamine in cell-culture fermentation processes has been developed. The enzymes glucose oxidase, glutamate oxidase and glutaminase were immobilized by means of cross-linking with glutaraldehyde on platinum thin-film electrodes integrated within a microfluidic channel. The biosensor chip was coupled to a flow-injection analysis system for electrochemical characterization of the sensors. The sensors have been characterized in terms of sensitivity, linear working range and detection limit. The sensitivity evaluated from the respective peak areas was 1.47, 3.68 and 0.28 μAs/mM for the glucose, glutamate and glutamine sensor, respectively. The calibration curves were linear up to a concentration of 20 mM glucose and glutamine and up to 10 mM for glutamate. The lower detection limit amounted to be 0.05 mM for the glucose and glutamate sensor, respectively, and 0.1 mM for the glutamine sensor. Experiments in cell-culture medium have demonstrated a good correlation between the glutamate, glutamine and glucose concentrations measured with the chip-based biosensors in a differential-mode and the commercially available instrumentation. The obtained results demonstrate the feasibility of the realized microfluidic biosensor chip for monitoring of bioprocesses.
Molke fällt im Rahmen der Käseherstellung allein in Deutschland in Mengen von über 11 Mio. Tonnen jährlich an. Dieses Nebenprodukt wurde trotz seines Reichtums an Milchzucker und Proteinen lange Zeit kaum industriell weiterverarbeitet und stellte ein bedeutendes Problem bei der Abwasserreinigung dar. Derzeit kommen meist kosten- und reinigungsintensive Membranfiltrationsverfahren bei der Auftrennung von Molke in ihre Hauptkomponenten Lactose und Molkenprotein zum Einsatz. Die Produkte finden vorwiegend in der Nahrungsmittelindustrie Anwendung als Süßungsmittel, Proteinzusatz oder Texturbildner. Die Mehrheit des Proteins wird dabei als Konzentrat bzw. Proteinpulver verarbeitet. Wegen der antibakteriellen, antiviralen und weiteren wertvollen physiologischen Eigenschaften der Molkeproteine stellt eine weitere Aufreinigung der einzelnen Molkeproteine für die pharmazeutische Industrie einen naheliegenden zusätzlichen Wertschöpfungsschritt dar. In Kooperation mit der Süd Chemie AG wurde damit begonnen, ein Verfahren zu entwickeln, das kostengünstige mineralische Adsorbentien verwendet. Bisher konnte die Abtrennung von Lactose von den Molkenproteinen aus verdünntem Molkekonzentrat in einem Verfahrensschritt ohne Vorbehandlung des Rohstoffs erfolgreich realisiert werden. Aktuelle Arbeiten beschäftigen sich mit der Verbesserung der Proteinbindekapazitätund chromatographischen Proteinauftrennung sowie dem Upscaling zum direkten Einsatz von Molkekonzentrat ohne Vorverdünnung.
NVS123 is a poorly water-soluble protease 56 inhibitor in clinical development. Data from in vitro hepatocyte studies suggested that NVS123 is mainly metabolized by CYP3A4. As a consequence of limited solubility, NVS123 therapeutic plasma exposures could not be achieved even with high doses and optimized formulations. One approach to overcome NVS123 developability issues was to increase plasma exposure by coadministrating it with an inhibitor of CYP3A4 such as ritonavir. A clinical boost effect was predicted by using physiologically based pharmacokinetic (PBPK) modeling. However, initial boost predictions lacked sufficient confidence because a key parameter, fraction of drug metabolized by CYP3A4 (ƒₘCYP3A4), could not be estimated with accuracy on account of disconnects between in vitro and in vivo preclinical data. To accurately estimate ƒₘCYP3A4 in human, an in vivo boost effect study was conducted using CYP3A4-humanized mouse model which showed a 33- to 56-fold exposure boost effect. Using a top-down approach, human ƒₘCYP3A4 for NVS123 was estimated to be very high and included in the human PBPK modeling to support subsequent clinical study design. The combined use of the in vivo boost study in CYP3A4-humanized mouse model mice along with PBPK modeling accurately predicted the clinical outcome and identified a significant NVS123 exposure boost (∼42-fold increase) with ritonavir.